A microfluidic biochip device includes a housing including at least one microchannel defining at least one cell adhesion region. The at least one cell adhesion region is provided with at least one capturing agent that adheres a cell of interest to a surface of the at least one microchannel when a fluid sample containing cells is passed through the at least one microchannel. An imaging system measures the morphology and/or quantity of cells of interest adhered by the at least one capturing agent to the surface of the at least one microchannel when the fluid sample is passed therethrough.

The present disclosure provides a micro-organismal product and a method for treating a patient with sickle cell disease. In one aspect, the method comprises determining a concentration of one or more biological markers in serum of the patient indicative of breach of an intestinal barrier in sickle cell disease; and administering a micro-organismal product to the patient that restores intestinal permeability of the patient by, for example, upregulating tight-junctions of the patient's intestine.

The invention disclosed herein is based on the identification of novel mutations in the JAK2 gene and JAK2 protein. The invention provides compositions and methods useful for diagnosing hematopoietic diseases including, for example, myeloproliferative diseases. The invention also provides compositions and methods useful for determining a prognosis of an individual diagnosed as having a hematopoietic disease.

A method is provided for calibrating a microfluidic system comprising, which method is based on using beads having a structure based on DNA origami, wherein said structure comprises a predetermined number of fluorophores. Furthermore, methods for determining the level of an antigen using microfluidics calibrated using fluorescent microbeads as provided herein. Also, methods are provided for determining the presence or state of a haematological disease by calibrated a microfluidics system.

Disclosed are nanoparticle compositions comprising nanoparticles prepared from denatured, cross-linked albumin and a therapeutic agent for treating a neutrophil-mediated inflammation, and methods of treating neutrophil-mediated inflammation using the compositions.

Provided are methods for assigning a subject having idiopathic multicentric Castleman disease (iMCD) to a group having a higher or lower probability of responding to treatment for iMCD using measured quantities of CXCL13. Also disclosed are methods of treating idiopathic multicentric Castleman disease (iMCD) in a subject in need thereof comprising administering to the subject an inhibitor of CXCL13 or of CXCR5. Also provided herein are methods for assigning a subject having idiopathic multicentric Castleman disease (iMCD) to a group having a higher or lower probability of responding to treatment for iMCD using measured quantities of specified biomarkers. The present disclosure also provides methods of treating idiopathic multicentric Castleman disease (iMCD) in a subject in need thereof comprising administering to the subject an inhibitor of the JAK-STAT3 pathway. Also disclosed are methods for assessing the absence or presence of iMCD in a subject.

The disclosure relates to bispecific antibodies against CD3 and BCMA for use in the treatment of diseases. The disclosure provides methods of determining the responsiveness of a patient to such treatment and relates to diagnostic assays.

Markers for genomic instability in Fanconi Anemia (FA) and other pathologies for therapeutic and diagnostic uses. In one embodiment, glycosphingolipid metabolism is altered in the FA deficient squamous cell carcinoma (SCC) cells, based on analysis of a metabolomics/lipidomics platform. The data indicated ganglioside metabolism was important in FA patients' susceptibility to SCC progression.

A whole blood filtration device is provided with a filter membrane separating a feeding volume and a clean side of the filter membrane from each other. The feeding volume communicates with a first feeding side opening and with a second feeding side opening. The filter membrane has pores with a pore size that ensures permeability of the filter membrane to blood plasma/serum and that retains blood cells. The first feeding side opening can be coupled to a first blood pump for feeding blood from the first feeding side opening into the feeding volume so that blood plasma/serum permeates the filter membrane and blood cells, retained by the filter membrane, exit from the feeding volume through the second feeding side opening.

Various implementations include devices, kits, and methods for diagnosing and monitoring disease states using rheological properties of a bodily fluid within a lateral flow membrane. The devices, kits, and methods enable rapid diagnosis and management of those diseases that alter the physical properties of bodily fluids within an in vivo context. The ability to rapidly diagnose and manage those diseases enables primary care providers to provide detailed interventions at the point of care.